Acinetobacter baumannii has emerged as a highly troublesome pathogen for many
institutions globally. As a consequence of its immense ability to acquire or upregulate …

Colistin is a polymyxin antibiotic that was discovered in the late 1940s for the treatment of
gram‐negative infections. After several years of clinical use, its popularity diminished …

The global emergence of multidrug-resistant gram-negative bacilli has spurred a renewed
interest in polymyxins. Once discarded due to concerns regarding nephrotoxicity and …

Institutional outbreaks caused by Acinetobacter baumannii strains that have acquired
multiple mechanisms of antimicrobial drug resistance constitute a growing public-health …

Colistin has been re-introduced into clinical practice for the treatment of carbapenem-
resistant Gram-negative bacteria. Studies in the last decade attempted to reconstruct the …

The emergence of multidrug-resistant (MDR) Gram-negative bacilli creates a challenge in
the treatment of nosocomial infections. While the pharmaceutical pipeline is waning, two …

The emergence of multidrug-resistant (MDR) Gram-negative bacilli creates a big problem for
the treatment of nosocomial infections. As the pharmaceutical pipeline wanes, the only …

Acinetobacter baumannii is an opportunistic Gram-negative pathogen with increasing
relevance in a variety of hospital-acquired infections especially among intensive care unit …

Multidrug-resistant Acinetobacter baumannii (MDRAB) presents an increasing challenge to
health care. Although colistin has been used as a treatment of last resort, there is concern …

Colistin is commonly the last resort for treatment of infections caused by multidrug-resistant
Gram-negative bacteria. In clinical practice, it is frequently used as combination therapy in …